This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Hepatic Insufficiency or Liver Insufficiency
and you are
between 18 and 80
years old
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

Study summary: "Liver transplantation and the reticuloendothelial clearance capacity." The purpose of this study is to evaluate the effect of liver transplantation on the immune system. This study will involve the taking of a number of observations but does not involve any treatment, which differs from normal care. Indications for transplantation are solely based on the best clinical practice, which is usually performed at the department. The study measures liver function based on the clearance of different "marker" substances by the liver. These substances are given intravenously and their clearance will be measured from bloodstream. All substances used in this study are registered in the United Kingdom for clinical applications and already used in clinical practice over years. They are safe and without any risk to harm individuals under study. Furthermore no side effects or any symptoms caused by the administration of these substances are expected. Measurements of liver function are undertaken before transplantation, 1 and 7 days following the transplant. There is no restriction from any of the patient's prescribed medication. All blood samples will be removed from the cannula (drip) and will not require repeated injections. It is hoped that this research will lead to a greater understanding of the effects of liver transplantation on the immune system.

Provided treatments

  • Radiation: Nanocoll®
Tris trial is registered with FDA with number: NCT00929032. The sponsor of the trial is University of Edinburgh and it is looking for 12 volunteers for the current phase.
Official trial title:
The Impact of Liver Transplantation on Reticuloendothelial Clearance Capacity